A new national-level analysis published in The Lancet provides the first robust evidence that high HPV vaccination coverage is linked to a significant decline in cervical cancer deaths. Researchers observed a substantial decrease in mortality among women aged 20 to 29 in England, particularly those vaccinated at ages 12 to 13. The study, led by Peter Sasieni and Milena Falcaro, analyzed population-based mortality data from 2001 to 2024.
The findings mark a long-awaited milestone in public health, as experts have waited two decades for signs that HPV vaccination prevents deaths, not just precancerous lesions or cancer incidence. Previous studies in Sweden, Denmark, and England had already shown 84–88% reductions in cervical cancer incidence among vaccinated versus unvaccinated women. This new research extends that evidence to mortality, supporting the World Health Organization's goal of eliminating cervical cancer as a public health problem.
The data from England is among the first national-level analyses to demonstrate an impact on deaths. The authors note that the observed decline is particularly pronounced in the cohort offered the vaccine at ages 12–13, the youngest age group eligible since the program began. The reduction aligns with the timing of vaccine rollout, strengthening the case for a causal effect.
The study's observational design means it cannot definitively prove causation, though the magnitude and timing of the decline are compelling. Experts urge continued efforts to achieve high vaccine uptake among young adolescents globally, especially in low- and middle-income countries where cervical cancer burden is highest. The findings reinforce that widespread vaccination can translate into real-world mortality reductions within a decade.
"These findings support the achievability of the WHO goal of eliminating cervical cancer as a public health problem," the authors write. Public health officials see this as a powerful testament to prevention's impact.